India’s deeptech funding record faces a test of scale: Speciale Invest report

India’s deeptech companies raised $914 million in 257 rounds in 2025, 34 times the 2016 level. The harder test is turning research and prototypes into commercial products, notes Speciale Invest’s report, India’s Deep Tech Revolution - From the Lab to Growth and Exits.
Using Tracxn data through August 31 2026, the study covers 8,293 private companies worldwide, including 482 in India. India accounted for 12.8% of deeptech funding rounds in 2025 but received 1.6% of the capital.
For every 100 seed rounds, India had 23 Series A or B rounds, against 105 globally. Separately, there was one late-stage or private-equity round per 100 Indian seed rounds, against 26 worldwide. Both measures point to funding thinning as companies mature.
Sectoral advantages are uneven. Space firms can tap ISRO testing facilities and suppliers, while life-sciences ventures can draw on India’s pharmaceutical manufacturing base. Private participation in space has widened since 2020 reforms. Registered space startups rose from one in 2014 to about 440 by August 2026.
In July, Skyroot’s Vikram-I became the first privately developed Indian rocket to reach orbit from Indian soil. It was a milestone, though one launch does not establish a repeatable commercial business.
The report says battery makers still rely on imported cells and materials. Separately, Exide commissioned phase one of a 6 GWh Bengaluru cell plant in September. Semiconductor developers remain reliant on overseas fabrication and packaging. Semicon 2.0, approved in July with Rs 1,27,500 crore, aims to expand domestic capacity; the first fab is due in 2028.
The six-year Rs 1 lakh crore Research, Development and Innovation Scheme aims to finance high-risk technology. By July 2026, the Technology Development Board had approved 22 projects with Rs 2,192 crore in support. Assistance is mainly through low-interest long-term loans, equity and equity-linked instruments, rather than standard grants.
Turning a successful pilot, or customer trial, into an order remains difficult. Vishesh Rajaram, managing partner at Speciale Invest, said, “Large companies and public-sector buyers can help turn those trials into commercial orders by agreeing upfront on what a pilot must prove and when they’ll make a purchase decision. A first order lets a startup plan production and commit to suppliers.”
Growth capital is smaller too. Indian Series A and B rounds averaged $11.5 million from January to August 2026, against $55.5 million globally, said Vishnu Rajeev, investment partner at Speciale Invest.
“That gap matters when a founder needs to qualify a product with a major customer or commission a production line before commercial revenue is predictable, Rajeev adds. He argues funding should match milestone costs, with project finance once customers make firm commitments.
The report urges faster funding decisions, shared testing facilities, more domestic Series B and C investors, and plant finance before pilots end. It also considers listings, acquisitions, licensing and secondary share sales as exit routes.
Deeptech needs not just research funding, but reliable customers and patient growth capital.
This content is published by YourStory and has not been created or edited by Hello Headlines. View original




